A Deeper Look into Immunotherapies in the Management of Advanced Renal Cell Carcinoma (RCC): Emerging Combination Options in an Evolving Treatment Paradigm

A continuing medical education activity sponsored by NAMCP and AAMCN.

Novel Treatment Approaches in the Management of Renal Cell Carcinoma (RCC): A Closer Look at Advances in Immunotherapy in an Evolving Treatment Paradigm is a 3-part live webinar series that will provide attendees with the latest information on Renal Cell Carcinoma

This is Part 2 of the series focusing on Immunotherapies in the Management of Advanced RCC

This activity is an archive from the webinar held July 31, 2019

This activity is valid from September 1, 2019 to October 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Merck Sharp & Dohme Corp.

Description:
Managed Care and clinical decision-making in the setting of advanced renal cell carcinoma (RCC) has been undergoing dramatic change in the past few years. The approval of new immunotherapeutic agents has expanded the lines of therapy available to patients, especially around combination options, and raised questions about how rational treatment planning and effective sequencing of new and older standards of care can optimize patient outcomes. Additionally, the benefit of real-world experience and data from subgroup analyses and long-term follow-up of landmark clinical trials continue to refine treatment strategies in advanced RCC.

Upon completion of this activity, participants will be able to:

  • Identify current unmet clinical needs in the management of advanced renal cell carcinoma (RCC) and evidence-based recommendations for the care of patients with these tumors

  • Review the efficacy and safety of approved and emerging immunotherapies in the management of advanced RCC

  • Examine recent clinical trial data on immunotherapy combination options in the management of advanced RCC

  • Analyze strategies to optimally sequence immunotherapy in advanced RCC management

  • Identify patients with advanced RCC who would potentially benefit from immunotherapies, either alone or in combination

     

Faculty: Toni K. Choueiri, MD
Director, The Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
The Jerome and Nancy Kohlberg Chair and Professor of Medicine
Harvard Medical School

Disclosure:

Dr. Choueiri has disclosed the following relationships and his presentation has been peer reviewed for any bias:
• Research (Institutional and personal): Analysis Group, AstraZeneca, Alexion, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Ipsen, Tracon, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Sanofi/Aventis, Takeda.
• Honoraria: Analysis Group, AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Heron Therapeutics, Lilly, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, NCCN, Michael J. Hennessy (MJH) Associates, Inc (Healthcare Communications Company with several brands such as OnClive, PeerView and PER), L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM, Lancet Oncology.
• Consulting or Advisory Role: Analysis Group, AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Heron Therapeutics, Lilly, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN
• No speaker’s bureau
• No leadership or employment in for-profit companies. Other present or past leadership roles: Director of GU Oncology Division at Dana-Farber and past President of medical Staff at Dana-Farber), member of NCCN Kidney panel and the GU Steering Committee, past chairman of the Kidney Cancer Association Medical and Scientific Steering Committee)
• Patents, royalties or other intellectual properties: related to immunotherapy predictors of response
• Stock: Pionyr, Tempest
• Travel, accommodations, expenses, in relation to consulting, advisory roles, or honoraria
• Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies (ClinicalThinking, Envision Pharma Group, Fishawack Group of Companies, Health Interactions, Parexel, Oxford PharmaGenesis, and others).
• The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter.
• CV provided upon request for scope of clinical practice and research
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue